Li YL, Cheng ZX, Yu FH, Tian C, Tan HY. Advances in medical treatment for pancreatic neuroendocrine neoplasms. World J Gastroenterol 2022; 28(20): 2163-2175 [PMID: 35721885 DOI: 10.3748/wjg.v28.i20.2163]
Corresponding Author of This Article
Huang-Ying Tan, MD, PhD, Professor, Department of Integrative Oncology, China-Japan Friendship Hospital, No. 2 Yinghuayuan East Street, Chaoyang District, Beijing 100029, China. tanhuangying@263.net
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. May 28, 2022; 28(20): 2163-2175 Published online May 28, 2022. doi: 10.3748/wjg.v28.i20.2163
Advances in medical treatment for pancreatic neuroendocrine neoplasms
Yuan-Liang Li, Zi-Xuan Cheng, Fu-Huan Yu, Chao Tian, Huang-Ying Tan
Yuan-Liang Li, Zi-Xuan Cheng, Fu-Huan Yu, Chao Tian, Huang-Ying Tan, Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing 100029, China
Yuan-Liang Li, Zi-Xuan Cheng, Fu-Huan Yu, Chao Tian, Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China
Author contributions: Li YL and Cheng ZX made equal contributions to this paper and should be regarded as a co-first author; Li YL and Cheng ZX searched the literature and wrote the manuscript; Yu FH and Tian C translated the manuscript; Tan HY revised the manuscript.
Supported byNational Key R&D Program of China, No. 2019YFB1309704.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Huang-Ying Tan, MD, PhD, Professor, Department of Integrative Oncology, China-Japan Friendship Hospital, No. 2 Yinghuayuan East Street, Chaoyang District, Beijing 100029, China. tanhuangying@263.net
Received: October 27, 2021 Peer-review started: October 27, 2021 First decision: December 27, 2021 Revised: December 31, 2021 Accepted: April 15, 2022 Article in press: April 15, 2022 Published online: May 28, 2022
Core Tip
Core Tip: Pancreatic neuroendocrine neoplasms (PanNENs) are rare neoplasms with strong heterogeneity. The systemic treatment options of advanced PanNENs vary due to the different differentiations, grades and stages and include somatostatin analogs, molecularly targeted agents, cytotoxic chemotherapeutic agents, immune checkpoint inhibitors, and peptide receptor radionuclide therapy. Despite the multiple systemic therapeutic options for PanNENs, problems such as drug resistance, adverse side effects and limited scope of application still exist. Thus, we review the clinical development of medical treatment options, focusing on ongoing clinical studies and the development of novel targeted drugs, to provide a reference for clinicians and researchers.
